Search clinical trials for: RTK Inhibitor

Total 65260 results

Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Completed

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands | Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Salivary Gland Cancers | ACC

Canada
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Terminated

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy (DOVE-M)

Advanced Malignant Pleural Mesothelioma | MPM

Canada
Ascentage Pharma Group Inc.

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL

Russian Federation
Manmeet Ahluwalia, MD
National Cancer Institute (NCI); Novartis

Completed

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Emory University

Terminated

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Principia Biopharma, a Sanofi Company
Principia Biopharma Australia Pty Ltd.

Completed

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Pemphigus Vulgaris

Israel, Australia, Greece, Croatia, France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Hepatic Impairment

Germany
Tesaro, Inc.

Completed

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United Kingdom, United States, Taiwan, Spain, Poland
Ruijin Hospital

Recruiting

A Combination Study of CAR-T Therapy in r/r B-NHL

Diffuse Large B Cell Lymphoma

China
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada, Australia, Puerto Rico
Peking University People's Hospital
Qilu Hospital of Shandong University; Beijing Tongren Hospital; Beijing Hospital and other collaborators

Not yet recruiting

Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

Immune Thrombocytopenia

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma
Jason Robert Gotlib
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Heather Wakelee
Novartis; Genentech, Inc.

Terminated

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IV

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Celgene
The Leukemia and Lymphoma Society

Completed

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | B Cell Non-Hodgkin's Lymphoma

United States
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Fudan University

Recruiting

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Non-small Cell Lung Cancer | Brain Metastases

China
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States, Canada, Singapore
Northwestern University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Active, not recruiting

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

HIV Infection

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Argentina, Chile, Mexico, Portugal, Malaysia, Panama, South Africa, Canada, Netherlands, Brazil, Puerto Rico, Austria, Russian Federation, Thailand, Hungary, Denmar... and more
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

HIV

United States, France, United Kingdom, Germany, Taiwan, Spain, Belgium, Chile, Costa Rica, Panama, South Africa, Canada, Greece, Singapore, Argentina, Mexico, Puerto Rico, Austria, Russian Federation, Thailand, Australia, Denmark, S... and more
The Cleveland Clinic

Completed

Heart-Brain Retraining for Stroke Rehabilitation

Stroke

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT)

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Reata, a wholly owned subsidiary of Biogen

Withdrawn

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Malignant Melanoma
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor

China
Andrew Rezvani
National Institutes of Health (NIH); Pharmacyclics LLC.

Completed

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
Toray Industries, Inc
Astellas Pharma Inc

Completed

TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Chronic Renal Failure | Glomerular Disease | Nephrosclerosis

China, Hong Kong, Taiwan, Malaysia, Japan, Korea, Republic of, Thailand
Bayer

Completed

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Solid Tumors Harboring NTRK Fusion

Germany
Kami Maddocks, MD

Active, not recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory/Relapsed Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

HIV Infection | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular... and other conditions

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Activating Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
University of Edinburgh

Withdrawn

Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer (RTM)

Breast Cancer
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States
Hospital Regional de Alta Especialidad del Bajio

Completed

The Mesh-RTL Project, for Prevention of Incisional Hernia (RTL)

Hernia Incisional

Mexico
Akros Pharma Inc.

Completed

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Hepatitis C Virus Infection, Response to Therapy of

Puerto Rico
University of Nebraska
National Cancer Institute (NCI)

Completed

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
Xinqiao Hospital of Chongqing

Unknown

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Stoke Therapeutics, Inc

Completed

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Dravet Syndrome

United States
Jennifer Woyach
Janssen Scientific Affairs, LLC

Completed

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Monoclonal Gammopathy of Undetermined Significance | Myelodysplastic Syndrome | Aplastic Anemia | Symptomatic COVID-19 Infection Laboratory-Confirmed | Monoclonal B-Cell Lymphocytosis

United States

Search clinical trials for: RTK Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations